Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation

Journal of Neuro-Oncology

Volumn 107, Issue 2, 2012, Pages 225-232

  Lieberman, Frank ^a   Yazbeck, Victor ^a   Raptis, Anastasios ^a   Felgar, Raymond ^a   Boyiadzis, Michael ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Central nervous system; Hematopoietic stem cell transplantation; Post transplant lymphoproliferative disorders; Rituximab

Indexed keywords

CD20 ANTIGEN; CD79A ANTIGEN; CYCLOSPORIN; GADOLINIUM; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TRANSCRIPTION FACTOR PAX5; VIRUS DNA; KI 67 ANTIGEN; PAX5 PROTEIN, HUMAN; RIBOSOME PROTEIN; RNA BINDING PROTEIN; RPL22 PROTEIN, HUMAN;

ACUTE LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLURRED VISION; BRAIN BIOPSY; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID ANALYSIS; CONTRAST ENHANCEMENT; DIPLOPIA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTEROPATHY; EPSTEIN BARR VIRUS; EYE MOVEMENT; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEADACHE; HISTOPATHOLOGY; HLA MATCHING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; LUMBAR PUNCTURE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; REVIEW; SKIN DISEASE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; B LYMPHOCYTE; BRAIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; METABOLISM; PATHOLOGY;

ADULT; B-CELL-SPECIFIC ACTIVATOR PROTEIN; B-LYMPHOCYTES; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KI-67 ANTIGEN; LYMPHOPROLIFERATIVE DISORDERS; MAGNETIC RESONANCE IMAGING; RIBOSOMAL PROTEINS; RNA-BINDING PROTEINS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84863568129     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0739-6     Document Type: Review

References (37)

1. Kaushansky K, Williams WJ (2010) Williams hematology. McGraw-Hill Medical, New York
2. Swerdlow S, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, World Health Orgnization, International Agency for Research on Cancer (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization International Agency for Research on Cancer, Lyon
3. Gottschalk S, Rooney CM, Heslop HE (2005) Post-transplant lymphoproliferative disorders. Annu Rev Med 56:29-44
4. Tsao L, Hsi ED (2007) The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 131:1209-1218
5. Cavaliere R, Petroni G, Lopes MB, Schiff D (2010) Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 116:863-870
6. Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA, Horowitz MM, Jaffe ES, Kingma DW, Travis LB, Flowers ME, Martin PJ, Deeg HJ, Curtis RE (2009) Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 113:4992-5001
7. DiNardo CD, Tsai DE (2010) Treatment advances inposttransplant lymphoproliferative disease. Curr Opin Hematol 17:368-374
8. Parker A, Bowles K, Bradley JA, Emery V, Featherstone C, Gupte G, Marcus R, Parameshwar J, Ramsay A, Newstead C (2010) Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. British journal of haematology 149:693-705
9. Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI (2010) Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. Current oncology reports 12:383-394
10. Aisa Y, Mori T, Nakazato T, Suzuki S, Suzuki N, Ikeda Y, Okamoto S (2009) Primary central nervous system post-transplant lymphoproliferative disorder presenting as cerebral hemorrhage after unrelated bone marrow transplantation. Transpl Infect Dis 11:438-441
11. Castellano-Sanchez AA, Li S, Qian J, Lagoo A, Weir E, Brat DJ (2004) Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol 121:246-253
12. Hamadani M, Martin LK, Benson DM, Copelan EA, Devine SM, Hofmeister CC (2007) Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR. Bone Marrow Transplant 39:249-251
13. Kordelas L, Trenschel R, Koldehoff M, Elmaagacli A, Beelen DW (2008) Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab. Onkologie 31:691-693
14. Nagafuji K, Eto T, Hayashi S, Oshima K, Maeda Y, Gondo H, Inamura T, Niho Y (1998) Donor lymphocyte transfusion for the treatment of Epstein-Barr virus-associated lymphoproliferative disorder of the brain. Bone Marrow Transplant 21:1155-1158
15. Nozzoli C, Bartolozzi B, Guidi S, Orsi A, Vannucchi AM, Leoni F, Bosi A (2006) Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 47:167-169
16. Pakakasama S, Eames GM, Morriss MC, Huls MH, Rooney CM, Heslop HE, Krance RA (2004) Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation 78:755-757
17. Terasawa T, Ohashi H, Tsushita K, Utsumi M, Mukai E, Nakamura S, Shimoyama M (2002) Failure to detect Epstein-Barr virus (EBV) DNA in plasma by real-time PCR in a case of EBV-associated posttransplantation lymphoproliferative disorder confined to the central nervous system. Int J Hematol 75:416-420
18. Verschuur A, Brousse N, Raynal B, Brison O, Rohrlich P, Rahimy C, Vilmer E (1994) Donor B cell lymphoma of the brain after allogeneic bone marrow transplantation for acute myeloid leukemia. Bone Marrow Transplant 14:467-470
19. Heslop HE (2009) How I treat EBV lymphoproliferation. Blood 114:4002-4008
20. Gerstner ER, Batchelor TT (2010) Primary central nervous system lymphoma. Arch Neurol 67:291-297
21. Taj MM, Messahel B, Mycroft J, Pritchard-Jones K, Baker A, Height S, Hadzic N, Pinkerton CR (2008) Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children. British journal of haematology 140:191-196
22. Nabors LB, Palmer CA, Julian BA, Przekwas AM, Kew CE (2009) Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate. Am J Transplant 9:1243-1248
23. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925-935
24. Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P, Fischer A, Morschhauser F, Salles G, Feremans W, Vilmer E, Peraldi MN, Lang P, Lebranchu Y, Oksenhendler E, Garnier JL, Lamy T, Jaccard A, Ferrant A, Offner F, Hermine O, Moreau A, Fafi-Kremer S, Morand P, Chatenoud L, Berriot-Varoqueaux N, Bergougnoux L, Milpied N (2006) Efficacy and safety of rituximab in B-cell post-transplantation lymphoprolif-erative disorders: results of a prospective multicenter phase 2 study. Blood 107:3053-3057
25. Choquet S, Oertel S, LeBlond V, Riess H, Varoqueaux N, Dorken B, Trappe R (2007) Rituximab in the management of posttransplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 86:599-607
26. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, Rooney CM, Heslop HE (2000) CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 95:1502-1505
27. Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, Reguerre Y, Stoppa AM, Bourquard P, de Hurault Ligny B, Dubief F, Mathieu-Boue A, Leblond V (2000) Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 11(1):113-116
28. Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Vary M, Babel N, Trappe RU, Jonas S, Hummel M, Anagnostopoulos I, Dorken B, Riess HB (2005) Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 5:2901-2906
29. Patrick A, Wee A, Hedderman A, Wilson D, Weiss J, Govani M (2011) High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder. J Neurooncol 103(3):739-743
30. Doolittle ND, Jahnke K, Belanger R, Ryan DA, Nance RW Jr, Lacy CA, Tyson RM, Haluska M, Hedrick NA, Varallyay C, Neuwelt EA (2007) Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk Lymphoma 48:1712-1720
31. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63:901-903
32. Santisteban M, Nieto Y, De la Cruz S, Aristu J, Zubieta JL, Fernandez Hidalgo O (2007) Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule. Clin Transl Oncol 9:465-467
33. Wong ET (2005) Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm. Expert opinion on pharmacotherapy 6:1107-1114
34. Wong ET, Tishler R, Barron L, Wu JK (2004) Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 101:139-145
35. Akyuz C, Aydin GB, Cila A, Akalan N, Soylemezoglu F, Cengiz M, Yazici N, Buyukpamukcu M (2007) Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child. Leuk Lymphoma 48:1253-1255
36. Canova F, Marino D, Trentin C, Solda C, Ghiotto C, Aversa SM (2011) Intrathecal chemotherapy in lymphomatous meningitis. Crit Rev Oncol Hematol 79:127-134
37. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA (2003) Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 101:466-468